IHC differentiated MPM from RMC with 100% specificity for both and sensitivities of 42.2% and 60.0%, respectively. The combination of MTAP and BAP1 IHC yielded a sensitivity of 77.8%, which was higher than that of BAP1 IHC alone or 9p21 FISH alone (62.2%). Moreover, a high degree of concordance was observed between the results of MTAP IHC and 9p21 FISH in cell blocks. CONCLUSIONS: A combination of MTAP and BAP1 IHC in cell blocks from pleural effusions appears to be a reliable and useful method for differentiating MPM cells from RMC and can be used in the routine diagnosis of MPM.
INTRODUCTION
Malignant pleural mesothelioma (MPM) is the most common primary neoplasm of the pleura and its incidence is closely linked to exposure to asbestos fibers. [1] [2] [3] The industrial use of asbestos currently is prohibited in Japan.
Nevertheless, the incidence of MPM has been increasing because of its latency period of 40 years. [4] [5] [6] The histologic diagnosis of MPM is not always straightforward. Immunohistochemistry (IHC) assays that differentiate between benign and malignant mesothelial proliferation, including antibodies against biomarkers such as glucose transporter 1 (GLUT-1), [7] [8] [9] [10] [11] CD146, [11] [12] [13] and oncofetal protein insulin-like growth factor 2 messenger RNA-binding protein 3 (IMP3), 9, 11, 14 have been described for the diagnosis of MPM. However, the diagnostic value of each biomarker remains controversial. Recent studies have revealed the usefulness of 2 new markers: homozygous deletion (HD) of the 9p21 locus detected by fluorescence in situ hybridization (FISH) 8, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] and BRCA1-associated protein 1 (BAP1) loss detected by IHC. 23, [27] [28] [29] [30] [31] Clinically, these markers are quite useful because they have 100% specificity for differentiating malignant mesothelial proliferations from benign proliferations. 32 Although the sensitivity of either of these markers is relatively insufficient, the combination approach of 9p21 FISH and BAP1 IHC has been found to enhance the sensitivity. 23, [32] [33] [34] 9p21 FISH is a useful and reliable assay for the diagnosis of MPM, but the FISH assay cannot be performed in all laboratories because of the skilled procedures involved and the higher costs. Therefore, we sought to identify a reliable IHC marker that could predict the HD status of the 9p21 detected by FISH. The 9p21 locus includes a cluster of genes such as cyclin-dependent kinase inhibitor 2A (CDKN2A, also known as p16), CDKN2B (also known as p15 INK4B ), p14 ARF , and methylthioadenosine phosphorylase (MTAP). [35] [36] [37] [38] [39] Among the protein products of the genes, MTAP was the most suitable IHC marker, demonstrating a correlation with the results of 9p21 FISH and the ability to distinguish MPM from nonneoplastic reactive mesothelial hyperplasia (RMH), with a specificity of 100% and a sensitivity of 45.1%. 26 Moreover, the combination of MTAP IHC and BAP1 IHC was reported to be able to detect MPM with a good sensitivity of 76.5%, which was higher than that of BAP1 IHC alone (60.8%) or 9p21 FISH alone (60.8%). 26 The objective of the current study was to investigate whether loss of MTAP expression detected by IHC, either alone or in combination with BAP1 IHC, is useful for distinguishing benign from malignant mesothelial proliferations in cell blocks obtained from pleural effusions.
MATERIALS AND METHODS

Case Selection
Cell blocks prepared from pleural effusions obtained from patients with MPM or non-MPM diseases with RMH were analyzed. The diagnosis of MPM was confirmed in tissue samples and the histologic subtypes of tumors were identified using the World Health Organization classification. 40 The mesothelial origin of the tumor was determined by IHC, using a combination of calretinin, podoplanin (D2-40), cytokeratin 5/6, and Wilms tumor 1 staining as positive mesothelial markers and thyroid transcription factor 1, Ber-EP4, and carcinoembryonic antigen as negative markers. The cytologic preparations of RMH were obtained from pleural effusions associated with pleuritis carcinomatosa, pneumonia, or cardiovascular disease. All cases were derived from the pleural lesion files of the pathology department at Fukuoka University Hospital in Fukuoka, Japan, including consultation cases, between 2005 and 2016. Anonymous use of redundant tissues and cells is part of the standard treatment agreement with patients at the study hospital when no objection is expressed. The Fukuoka University Hospital Institutional Review Board approved the study protocol (approval number 11-7-11), which allowed a waiver of informed consent for the study.
Cell Block Preparations and Immunostaining of MTAP and BAP1
Less than 0.5 mL of pleural effusion was transferred into a polypropylene tube and then centrifuged at 3000 rpm for 2 minutes. The supernatant fluid was discarded and formalin (10% neutral buffered formalin) was added to the pellet to fix cells for at least 12 hours, followed by paraffin embedding.
Immunostaining was performed on 4-lm-thick cell block sections that were mounted on a glass microscope slide. After blocking the endogenous peroxidase activity using blocking reagent (included in the Dako EnVision Kit; Dako, Carpinteria, California) for 5 minutes at room temperature (RT), epitopes were retrieved using Trisethylenediaminetetraacetic acid (EDTA) buffer (pH 9.0) for 40 minutes at 95 8C followed by incubation with mouse monoclonal antibody (M01) MTAP clone 2G4 (1:100 dilution at RT for 30 minutes; Abnova, Taipei, Taiwan) or mouse monoclonal anti-human BAP-1 clone C-4 (1:50 dilution at RT for 45 minutes; Santa Cruz Biotechnology, Santa Cruz, California). The sections then were washed and incubated with the ChemMate EnVision kit (Dako). Immunoreactive cells were visualized using diaminobenzidine (Dako) followed by a hematoxylin counterstain.
Nonmesothelial cells that were immunoreactive to BAP1 and MTAP (eg, inflammatory cells including histiocytes and lymphocytes, fibroblasts, pneumocytes, and endothelial cells) served as internal positive controls in each staining protocol. BAP1 IHC revealed staining in the nucleus, and BAP1 loss in tumor cells was defined as nuclear staining at an intensity lower than that of the internal positive control. Cytoplasmic staining was interpreted as a nonspecific reaction. MTAP IHC revealed cytoplasmic as well as nuclear staining, and MTAP loss detected by IHC in tumor cells was defined as cytoplasmic and nuclear staining at an intensity lower than that of the internal positive control. Representative cases of BAP1 and MTAP IHC are shown in Figure 1 . The percentage of positive cells was determined by evaluating at least 500 mesothelial cells per sample. For all cases included in the study, the diagnosis of mesothelioma was supported by histological examination at the time of diagnosis. If the corresponding tissue specimens were available at the time of the current study, IHC expression of BAP1 and MTAP in cell block was compared with that in corresponding tissue specimens.
FISH Assay
The FISH studies were performed on 4-lm-thick tissue cell block sections as previously described. 21, 41 Sections were deparaffinized and rehydrated using descending alcohol dilutions, then washed with 2 3 saline sodium citrate (SSC) exposed to pretreatment solution at 80 8C for 30 minutes (PathVysion HER2 DNA probe kit; Vysis, Downers Grove, Illinois), and digested with pepsin solution (Sigma-Aldrich, Tokyo, Japan) at 37 8C for 90 minutes. After refixation in 10% buffered formalin at RT for 10 minutes, the sections were treated with 2 3 SSC, dehydrated in ethanol, dried, and exposed to either of the 2 probes:190-kilobase Vysis LSI p16/CEP 9 (Abbott Japan, Tokyo, Japan) or 57-kilobase SureFISH 9p21.3 CDKN2A (Agilent Technologies, Santa Clara, California). Both the probes and tissue sections were denatured at 80 8C for 10 minutes in the probe solution provided (Abbott Japan), followed by hybridization at 37 8C for 20 hours in ThermoBrite (Abbott Japan). Finally, the tissue sections were washed with 2 3 SSC containing 0.3% Tween 20 (Sigma Chemical Company, St. Louis, Missouri) at 72 8C for 2 minutes and then with 2 3 SSC containing 0.1% Tween 20 at RT for 5 minutes. Nuclei were counterstained with 4'6-diamidino-2-phenylindole (DAPI) in the antifade reagent (Vector Laboratories, Burlingame, California). Analyses were performed using a fluorescence microscope (Axio Imager Z1; Carl Zeiss MicroImaging, Jena, Germany) and Isis analysis system (MetaSystems, Altlussheim, Germany) equipped with filter sets with singleband and dual-band exciters for spectrum green, spectrum orange, and DAPI (ultraviolet, 360 nm 
RESULTS
Clinicopathological Characteristics of the Cases
In the current study, cell blocks from 52 cases of MPM and 30 non-neoplastic cases with RMH were initially examined. However, 15 samples (18.3%) were excluded because of insufficient mesothelial cells (11 samples; 13.4%) or inadequate immunostaining of internal control cells (4 cases; 4.9%). One case (6.3%) that harbored a monosomy of chromosome 9 detected by FISH also was excluded. Eventually, 45 cases of MPM and 21 nonneoplastic cases with RMH were included in the current study. The MPM cases were 34 men and 11 women with a mean age of 69.7 years (range, 47-94 years), and included 42 epithelioid and 3 biphasic MPM cases. Non-neoplastic RMH cases were 12 men and 9 women with a mean age of 70.5 years (range, 44-89 years), and included benign pleural effusions from patients with lung cancer (14 cases), pneumonia (3 cases), and cardiovascular disease (4 cases).
MTAP and BAP1 Immunostaining in Cell Blocks
In cell blocks, in which MPM cells were arranged as clusters, we assessed IHC results in the clustered MPM cells. A
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representative case is shown in Figure 2 . In cell blocks that contained only scattered individual MPM cells, we performed double immunostaining with a combination of antiepithelial membrane antigen (EMA) and MTAP antibodies or anti-EMA and BAP1 antibodies. This double immunostaining approach enabled the morphological 
Determination of Cutoff Values for MTAP IHC, BAP1 IHC, and 9p21 FISH
The cutoff value for HD of 9p21 as detected by FISH was set as 10%, as described previously. 21, 26, 34, 43 To assess the detection of MTAP and BAP1 losses by IHC, we previously suggested assigning an easily evaluable cutoff value of 50% for clinical use because the percentage of cells positive for BAP1 or MTAP in MPM cases exhibit a bimodal distribution; cases that are positive for staining exhibit a high percentage of positivity, and cases that are negative for staining exhibit a low percentage of positivity. 26 Thus, in the current study, we set the cutoff value at 50% for MTAP IHC and BAP1 IHC. The distributions of the percentages of immunopositive cells are shown in Figure 4 . 
Sensitivity and Specificity of Detection Assays for Distinguishing MPM Cells From Reactive Mesothelial Cells in Cell Blocks
The sensitivity and specificity of MTAP IHC, BAP1 IHC, and 9p21 FISH for distinguishing MPM cases from nonneoplastic cases with reactive mesothelial cells are summarized in Table 3 . MTAP and BAP1 IHC each were characterized by a specificity of 100% and sensitivities of 42.2% and 60.0%, respectively. Their combination yielded a sensitivity of 77.8%, which was higher than that of either BAP1 IHC alone (60.0%) or 9p21 FISH alone (62.2%). A combination of 9p21 FISH and BAP1 IHC exhibited the highest sensitivity of 84.4%.
DISCUSSION
To the best of our knowledge, the current study is the first to demonstrate that MTAP IHC, when used in combination with BAP1 IHC, is useful for distinguishing benign and malignant mesothelial proliferations in cell blocks prepared from pleural effusions. For such differentiation, it previously was reported that a combination of BAP1 IHC and 9p21 FISH was useful in cell blocks from pleural effusions. 44 However, the FISH technique is not available in all institutions or laboratories. In tissue samples, we recently demonstrated that MTAP IHC is a good alternate assay with which to predict 9p21 HD status as detected by FISH. 26 In the current study, we examined the diagnostic usefulness of MTAP IHC in cell blocks from pleural effusions. The sensitivity of MTAP IHC was relatively unsatisfactory (42.2%), but increased in combination with BAP1 IHC to 77.8%, which was higher than that of BAP1 IHC alone or 9p21 FISH alone, while maintaining a specificity of 100%, indicating that this combination of IHC assays could be used in routine practice for the diagnosis of MPM. MPM is an aggressive malignancy, with a median overall survival ranging from 9 to 17 months. 1 The early detection of MPM is a clinical priority because the treatment of MPM in its early stage would improve outcomes. 45, 46 Histopathologically, the demonstration of stromal or fat invasion has been a key feature in the diagnosis of MPM. 35, 47 However, it is not always feasible to obtain adequate tissue with which to make the histologic diagnosis because of a patient's deteriorated performance status and impaired respiratory function. Meanwhile, pleural effusion usually is the first clinical sign of MPM, and is reportedly observed in 54% to 89% of patients with MPM. 21, 35, [47] [48] [49] [50] Recent studies have demonstrated that HD of 9p21 positivity detected by FISH and BAP1 loss detected by IHC in pleural effusions may allow for a diagnosis of MPM without an additional tissue biopsy, if clinical and radiological findings also support the diagnosis, because such loss in mesothelioma cells in cytological specimens correlated with those in tissues. 8, 16, 22, 31, 43, 44, 51 In the current study, we demonstrated that MTAP IHC can be a viable alternate assay in cell blocks for 9p21 FISH. MTAP, which resides on the telomeric side of p16, encodes an enzyme (5'-deoxy-5'-methylthioadenosine phosphorylase) that plays an important role in polyamine metabolism and salvage of adenine and methionine. [52] [53] [54] MTAP is ubiquitously expressed in all normal human tissues, and has been reported to be deleted in a variety of tumor types. 52, 54, 55 As we reported previously, MTAP IHC can predict the HD status of 9p21 detected by FISH in tissue samples for the diagnosis of MPM. 26 In the current study, we demonstrated that loss of MTAP IHC had a specificity of 100% for predicting the HD of 9p21 detected by FISH; however, approximately 32.1% of 9p21 HD-positive cases detected by FISH demonstrated no loss of MTAP expression by IHC. It is reported that the MTAP gene deletion does not occur alone in MPM. Rather, the MTAP gene deletion in MPM only occurs as a codeletion with the p16 gene. However, there are cases known to occur that involve p16 gene deletion without the concomitant MTAP gene deletion. 52 Therefore, 9p21
FISH is recommended to be performed in cases in which MTAP loss is not detected by IHC despite the high clinical possibility of MPM. Original Article BAP1 is a nuclear ubiquitin hydrolase located at the epicenter of 3p21.1 and controls several functions, including DNA repair, cell proliferation, and the expression of genes related to cell cycle. 29, 56 Biallelic BAP1 gene mutations lead to BAP1 loss detected by IHC, whereas monoallelic mutation does not cause BAP1 loss. 28, 29, 57 BAP1 loss detected by IHC is observed in 56% to 81% of epithelial mesotheliomas, which is more frequent than observed in either biphasic (45%-60%) or sarcomatoid mesothelioma (15%-63%). 32, 40 In the current study, BAP1 loss was detected by IHC in 60.0% of cases. In addition, epithelial mesotheliomas are observed much more frequently than sarcomatoid mesothelioma in pleural effusions. 32, 40 Thus, BAP1 loss detected by IHC is a useful marker for the cytologic detection of MPM.
In cell blocks obtained from pleural effusions, it occasionally was difficult to morphologically differentiate MPM cells from reactive mesothelial cells or histiocytes, especially in immunostained sections wherein MPM cells were present as single cells. In such cases, we performed double immunostaining using an anti-EMA antibody and assessed the loss of MTAP or BAP1 expression in the EMA-positive mesothelial cells. The sensitivity and specificity of EMA in distinguishing MPM from RMH is reportedly approximately 75% each. 58, 59 Therefore, EMA is not a viable IHC marker for distinguishing MPM from RMH; however, EMA still is useful to differentiate mesothelioma cells from non-neoplastic reactive mesothelial cells. 42 In the current study, double immunostaining using EMA/MTAP or EMA/BAP1 enabled the assessment of scattered MPM cells in the cell blocks from pleural effusions. However, because of its immunoreactivity in plasma cells and adenocarcinoma or squamous cell carcinoma cells, EMA IHC requires careful interpretation. Thus, confirmation of the mesothelioma origin of cells by morphology and IHC is necessary when using double immunostaining for the diagnosis of mesothelioma. 58, 60 The current study has a few limitations. First, it included only epithelioid and biphasic MPMs, in which tumor cells often are present in pleural effusions. The sarcomatoid subtype rarely is diagnosed using effusion cytology because the cells do not usually appear in pleural effusions. 40 Second, there are some concerns regarding the interpretation of MTAP and BAP1 IHC. We excluded 11 cases from the current analysis because of insufficient numbers of mesothelial cells. In such cases, reexamination is recommended. In addition, assessment of MTAP loss could not be performed because of weak and heterogeneous MTAP staining in a few cases (4.9%). In cases in which the interpretation of MTAP IHC is difficult despite the presence of atypical mesothelial cells, 9p21 FISH to confirm the HD status of p16 in the cell block or tissue biopsy is suggested. Finally, the number of cases analyzed was relatively small. Further studies are needed to confirm the usefulness of MTAP IHC. A combination of MTAP and BAP1 IHC in cell blocks from pleural effusions was found to be a reliable and useful method for differentiating MPM cells from reactive mesothelial cells when the results were interpreted properly and accurately.
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